Obeldesivir

• CAT Number: I043441
• CAS Number: 2647441-36-7
• Molecular Formula: C16H19N5O5
• Molecular Weight: 361.35
• Purity: ≥95%
• Synonyms: [(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methyl 2-methylpropanoate
• InChI: InChI=1S/C16H19N5O5/c1-8(2)15(24)25-5-10-12(22)13(23)16(6-17,26-10)11-4-3-9-14(18)19-7-20-21(9)11/h3-4,7-8,10,12-13,22-23H,5H2,1-2H3,(H2,18,19,20)/t10-,12-,13-,16+/m1/s1
• InChIKey: YIHPGVCWGSURHO-VSBTWAGUSA-N
• SMILES: CC(C)C(=O)OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O

Obeldesivir（Cat No.:I043441）is an investigational antiviral drug under development for the treatment of viral infections, particularly COVID-19. It works as a nucleoside analog, inhibiting the replication of viral RNA by interfering with the viral RNA polymerase. By disrupting the virus’s ability to replicate its genetic material, Obeldesivir aims to reduce the severity and duration of infections. It has shown promise in preclinical and clinical studies as a potential therapeutic option for patients with viral infections, including those caused by SARS-CoV-2. Further studies are ongoing to evaluate its efficacy and safety in treating various viral diseases.